Hikal Ltd
Hikal Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Hikal anticipates high teens year-on-year CAGR growth over the next 3 to 5 years, targeting mid- to high teens annual growth. Hikal anticipates mid- to high-teens CAGR growth over the next 3 to 5 years, targeting FY'28 as a reference point for progress.
From Hikal Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Hikal anticipates high teens year-on-year CAGR growth over the next 3 to 5 years, targeting mid- to high teens annual growth.
- By FY '28, revenue to grow significantly from FY '24 levels, supported by new product launches in Pharma and Agrochem sectors.
- Pharma business growth driven by 13-14 CDMO products in pipeline, two near commercialization by FY '26 end; majority launching FY '27 onwards.
- Crop protection division sees stabilization with increasing domestic demand and innovative CDMO projects; 8 active CDMO products in pipeline.
- Veterinary segment expected to grow to INR400+ crores over the next 5 years, becoming a standalone division.
- Project Pinnacle strategy to enhance market positioning, operational efficiency, and support sustained revenue and margin growth.
2 more points from Hikal Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current year capex is guided at INR140 crores to INR150 crores, as per earlier guidance.
- For FY '26, planned capex is around INR150 crores to INR200 crores annually.
- Of this, 30% to 40% will be replacement and maintenance capex, with the balance allocated to debottlenecking and growth capex.
- The Agrochem plant capitalization amounted to INR340 crores last month.
- The company is continuously investing about 4.5% to 5% of revenue into R&D to drive innovation and meet customer demands.
2 more points from Hikal Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No explicit details on the current or expected order book or pending orders were provided in the transcript.
- The company mentioned having a strong pipeline with:
- About 13 to 14 Pharma CDMO products in Phase II and III trials.
- Several projects in Crop Protection CDMO with a strong pipeline of eight products.
- Positive traction and an increase in RFP inflows from innovator customers across Pharma, Animal Health, and Crop Protection segments were reported.
- Validation of Animal Health portfolio is in progress with several new client engagements.
2 more points from Hikal Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal's management said in earlier quarters
Arthneeti Pro · Annual
Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hikal Ltd Q3 FY25 results?
Hikal anticipates high teens year-on-year CAGR growth over the next 3 to 5 years, targeting mid- to high teens annual growth. Hikal anticipates mid- to high-teens CAGR growth over the next 3 to 5 years, targeting FY'28 as a reference point for progress.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Current year capex is guided at INR140 crores to INR150 crores, as per earlier guidance.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.